NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19

Launched by NYU LANGONE HEALTH · Mar 22, 2022

Keywords

ClinConnect Summary

The NIH RECOVER Tissue Pathology study is examining the long-term effects of COVID-19, particularly in people who have experienced symptoms for an extended period after their initial infection. Researchers want to understand how COVID-19 can impact health even after recovery, focusing on individuals who died more than 30 days after showing symptoms, whether they were hospitalized or not. This study involves performing autopsies to analyze the tissues of those who had COVID-19 to uncover any lasting damage or health issues related to the virus.

To participate in this study, individuals must have had suspected or confirmed COVID-19 infections, with various criteria for inclusion such as experiencing specific symptoms or being in high-risk environments before getting sick. Importantly, there are no restrictions based on age, sex, or underlying health conditions, which means a diverse range of people can be included. While participants won’t be involved in taking any active steps during the study, their autopsy results will help researchers learn more about the potential long-term effects of COVID-19, contributing to better understanding and treatment of post-COVID conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with suspected SARS-CoV-2 infection
• 1. Patients who meet the clinical and epidemiological criteria listed below:
• • Clinical criteria: Acute onset of fever and cough or acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status.
• Epidemiological criteria:
• • 1. Having resided or worked in an area with a high risk of transmission of virus: closed residential, school, or camp settings any time within the 14 days before symptom onset; or
• • 2. Having resided or traveled to an area with community transmission any time within the 14 days before symptom onset; or
• • 3. Any known household contact or any member of the household working in any health care setting, including within health facilities or within the community, any time within the 14 days before symptom onset.
• • 2. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2 Antigen-RDT.
• • Patients with probable SARS-CoV-2 infection
• • 1. A patient who meets clinical criteria above AND is a contact of a probable or confirmed case or linked to a COVID-19 cluster; or
• • 2. A suspected case with chest imaging showing findings suggestive of COVID-19 disease; or
• • 3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause; or
• • 4. Death, not otherwise explained, in an adult with respiratory distress preceding death AND who was a contact of a probable or confirmed case or linked to a COVID-19 cluster.
• • Patients with confirmed SARS-CoV-2 infection
• • 1. A person with a positive Nucleic Acid Amplification Test (NAAT); or
• • 2. A person with a positive SARS-CoV-2 Antigen-RDT AND meeting either the probable case definition or suspected criteria a) or b); or
• • 3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who was a contact of a probable or confirmed case.
• General Eligibility Notes:
• • 1. Decedents with or without history of MIS-A or MIS-C are eligible;
• • 2. Decedents with or without history of SARS-CoV-2 vaccination are eligible;
• • 3. Decedents with recurrent SARS-CoV-2 infections and those with post-vaccination (breakthrough) infections are eligible;
• • 4. Decedents are eligible without exclusion related to sex, race/ethnicity, geography, nationality, severity of disease, or underlying health conditions.